than the LET of beta particles, translating into high rates of biologic damage (2) . Tissue damage, and cellular kill, is predominantly in the form of DNA strand breaks, with a propensity for the alpha-induced breaks to be double stranded and lethal. In general double strand breaks are difficult to repair via normal DNA repair mechanisms (3) . The potential role of immunologic factors in radiation induced cell kill has been hypothesized as well (4) .
Some alpha particles such as 223-radium ( 223 Ra) and 224 Ra can be used as naked molecules given their bonetargeting abilities. Most alphas however require targeting to the proper site once injected into a cancer patient. Thus, targeted alpha therapies (TATs) require a guiding molecule that delivers the isotope to the region of interest. Most TATs are comprised of a component that binds regions of biologic interest, a chelate to hold the radionuclide in place, and the active radioactive particle (5, 6) .
A variety of molecules have been used to guide the radiopharmaceutical to the location of interest. Antibodies and their derivatives (minibodies, diabodies, various fragments, etc.) are of course logical compounds that can deliver chelates precisely to cancerous locations and these have been used in a number of clinical studies. Small molecules can also be used and most prostate focused therapies to date have focused on molecules capable of binding a molecule called prostate specific membrane antigen (PSMA) which is over-expressed on a number of prostate cancer cells (vide infra). Imaging with PSMA ligands indicates the specificity of the interaction (7) . For other tumors, alphas can be directed to tumor tissue by a variety of targeting agents such as substance P, somatostatin analogues, various other peptides, small molecules, nanoparticles, and polymers (5, 6, 8, 9 Ac have multiple [4] [5] alpha decays before they reach stability. Though multiple alpha emissions provide greater opportunities for tumor kill, the diffusion of daughters also provide opportunities for untargeted cellular damage.
223 Ra is FDA approved in prostate cancer and is being investigated in multiple USA based clinical trials and will be discussed in detail below. 227 Th is conjugated to a CD22 directed antibody and is currently in a first-inman USA-based phase I (NCT02581878). 225 Ac is in an active clinical trial conjugated to an antibody to CD33 (lintuzumab) in older patients with acute myeloid leukemia (AML) (NCT02575963) and in a randomized trial for AML patients using a
225
Ac conjugated anti-CD45 antibody prior to stem cell transplant (NCT02665065). Not all ex-USA based trials are registered thus it is difficult to know with certainty where active alpha-emitter clinical trials are ongoing outside of the USA. Investigators in New York, USA; Heidelberg, Germany; and Pretoria, South Africa have reported very recent experiences in prostate cancer patients using alpha emitters.
Upon alpha emission, there is a substantial recoil and the alpha particle derived nucleus (100-200 KeV), is disengaged from the binding any chelate designed to date (and likely higher than any chelate designed in the future) (10) . The recoil energy post-alpha emission is simply higher than the chemical bonds that radionuclide in place. Recoil places Ra, thus no chelate is required (11) . In fact, attempts to create stable chelates with radium isotopes to date has been unsuccessful. 223 Ra has a half-life of approximately 11.4 days then decays with a total of 3 additional alpha emissions (11) . redistributed from the site of radium decay in the bone to soft tissues. It was found that the absorbed dose received by the marrow, a critical organ for potentially limiting normal tissue toxicity, would be considerably lower than that from 89 Sr due to short range of the alpha particle from 223 Ra compared to the longer range of the high energy beta from 89 Sr. In a companion rodent study (13) , it was demonstrated that 223 Ra has a significant antitumor effect in a bone metastases model. A significantly higher symptom-free survival was seen in the bone-tumor bearing rats (MT-1 breast cancer cell) administered 6 and 11 kBq of 223 Ra, with 36% of the animals treated with 11 kBq having improved symptom-free survival as compared to control rats (that developed tumor-induced paralysis within 20-30 days). In another treatment regimen, animals were administered with a bisphosphonate (pamidronate) after injecting 0, 5, 10 or 30 kBq of 223 Ra. The group receiving pamidronate alone has no survivors beyond 21 days, suggesting no therapeutic effect from this bone resorption inhibitor. Two out 5 animals from the 10 and 30 kBq groups survived for more to bone marrow. Another pre-clinical study to study the acute toxicity after iv administration of potentially toxic amounts of 223 Ra in Balb/c mice was then conducted (14) .
Results suggested that high amounts 223 Ra did not completely inactivate the blood-producing cell, which could be due to the distant location of red bone marrow cells from the bone surface (thus not affected by the short-range alpha-particles), and also the lost blood-producing cells being compensated by the recruitment of blood forming progenitor cells.
Ra in canines had shown affinity for and stability within calcified tissues (15) . Elimination of radioactivity was mainly via the intestine, as it is in humans.
223
Ra resided in transit within the gut content with minimal activity in intestinal walls. The highest concentration of 223 Ra as determined by alpha-track micro-autoradiography, was found on the surfaces of trabecular bone, with concentration in osteoblastic bone matrix.
Clinical trials for 223 Ra
Encouraged by the positive pre-clinical results, a phase I study was initiated to find the safety and tolerability of 223 Ra in breast and prostate cancer patients with bone metastases and to evaluate pain palliation (16 (19) . Eligibility criteria include bone metastatic CRPC patients who had received, were not eligible to receive, or declined chemotherapy. Patients with visceral disease or nodal metastases more than 3 cm (short axis) were excluded. Patients were randomized in 2:1 fashion to receive best standard of care (SOC) + 6 injections of 223 Ra (50 kBq per kilogram of body weight intravenously), or matching placebo, with injections every 4 weeks. Best standard of care included virtually any hormonal therapy used at that time (bicalutamide, estrogens, dexamethasone, prednisone, ketoconazole, etc.), bisphosphonates, or external beam radiation. Excluded concomitant therapies included chemotherapies and experimental therapies. A total of 921 patients were enrolled and stratified according to prior use (yes or no), baseline alkaline phosphatase level (<220 U per liter vs. ≥220), and current use or no use of bisphosphonate. The study endpoints were defined as: overall survival (primary endpoint), time to first symptomatic skeletal event (SSE), time to total alkaline phosphatase (ALP) progression, total ALP response, total ALP normalization, time to PSA progression, safety and quality of life (secondary endpoints). The majority of patients were with advanced disease (a large number of metastatic localizations). The trial was stopped at interim by the data monitoring committee for predefined overall survival (OS) benefit. Those Ra versus 14% in placebo, and diarrhea 25% vs. 15% (higher in those with radionuclide therapy). Based on these pivotal data (19),
223
Ra therapy was approved by regulatory agencies around the world.
Analysis of stratified subsets in the ALSYMPCA trial has led to additional insights regarding this agent (20, 21 Ra combined with abiraterone/prednisone in men with bone-metastatic CRPC and call into question the wisdom of combining 223 Ra with abiraterone until more safety data are available.
PSMA TATs
PSMA is a glutamate carboxypeptidase encoded by the FOLH1 (folate hydrolase 1) (24). The human enzyme contains 750 amino acids with most of the enzyme resides in the extracellular space. PSMA highly expressed in the vast majority of human prostate cancers and a multiplicity of studies indicate that both localized and metastatic adenocarcinomas of the prostate cancers express PSMA (25) . Normal tissue expression of PSMA (outside of the prostate) is limited and studies indicate expression is limited to normal prostate tissue, small bowel, proximal renal tubules, salivary glands, and astrocytes (26) . Lacrimal glands show uptake on PSMA scans as well. In tumors, PSMA expression has been linked to adverse prognosis and progression in many studies (27) but noteworthy is the fact that only adenocarcinomas express PSMA, small cell cancers do not express PSMA. Cell lines that lack AR do not express PSMA. Small molecule PSMA based imaging show high specificity for prostate cancer lesion and also uptake in the kidney, salivary glands, and lacrimal glands (28, 29) . Interestingly the PSMA targeted antibodies do not show salivary/lacrimal gland uptake leading to speculation that the uptake seen on small molecule scans may not be fully explained by PSMA expression. A number of small molecule ligands have been used in PSMA targeted radionuclides. These compounds can be classified into urea-based compounds, glutamate phosphoramidates and 2-(phosphinylmethyl) pentanedioic acids (30) . A large number molecules capable of binding tightly to PSMA have been synthesized and patented. Among these compounds, two are particularly in active clinical development (PSMA-617 and DCFPyL) which can serve in both imaging and therapeutic capacities. Thus these molecules are referred to as theragnostic agents (7) .
Several PSMA small molecules (PSMA-617, PSMA I&T, MIP-1095) have been used with beta-emitters such as lutetium-177 ( 177 Lu) or iodine-131 ( 131 I) (31) . Limited studies are available with PSMA-617 using Ac-225 and Bi-213. These will be covered in detail below. 225 Ac represents a production challenge but several sites have now produced 225 Ac including the Oak Ridge National Laboratories in the USA, the TRIUMF facility in Canada, the Institute for Transuranium Elements in Germany, and the ROSATOM State Corporation in Russia. The group in Heidelberg has been the pioneer in Ac-PSMA targeted therapy (32) . The initial report indicated remarkable responses in two heavily pretreated patients (32) . The first patient was treated as a 9 th line therapy with 3 cycles of 100 kBq/kg of 225 Ac-PSMA-617 at 2-month intervals, then a later fourth cycle consolidation at a lower dose of 6 MBq. The second patient received 100 kBq/kg dosing for 3 cycles given at 2-month intervals. Xerostomia was notable for both patients but no other adverse effects were reported. Hematologic parameters indicated no significant adverse effects despite the clear anti-tumor effects. Responses, as assessed by PSA declines and PSMA imaging were remarkable but no cross sectional or other imaging modalities were utilized thus leaving open the possibility that non-PSMA producing tumors were not assessed. The PSA decline was dramatic despite multiple prior therapies. The second patient had been previously treated and relapsed after multiple therapies including 177 Lu-PSMA indicating that TAT can overcome resistance to targeted beta therapy, a concept previously shown in neuroendocrine tumors (33) . 
Future considerations
The clinical development of 223 Ra is proceeding in multiple combination trials using immunotherapies such as PD-1 inhibitors, inhibitors of DNA repair (PARP inhibitors, ATR inhibitors), various hormonal therapies and chemotherapies (including docetaxel) that may serve as radiation sensitizers (see Table 1 for combination trials in progress). There is an intense interest to study DNA damaging agents such as 223 Ra in patients with known DNA repair defects (such as BRCA2) as those patients may be especially susceptible to such treatments (37) . Though preliminary data on repeat radium are available (38) , more data are needed. The increased fracture rate and death rate leading to the ERA-223 unblinding is a serious issue for 223 Ra that will need additional careful study given the unanticipated safety signal (23) . Though biomarker dynamics after 223 Ra have been studied (39) , clearly more data are needed to better understand biomarkers associated with response and progression after
223
Ra treatments. TAT is ongoing and developing on multiple fronts in prostate cancer with a focus on the PSMA targeting molecules. Both antibodies and small molecules will likely continue to drive TAT progress in multiple diseases (40) (41) (42) . Th platforms are going forward in prostate trials. Necessary trials will include conventional endpoints such as PSA declines, tumor shrinkage as measured by soft tissue cross-sectional assessments, progression-free survival, and overall survival. Careful adverse events assessment using conventional common toxicity criteria (CTC) criteria are needed. To prove utility for TAT, such therapies will need comparison to appropriate therapeutic alternatives in randomized trials. Safety issues with TAT are yet to be fully assessed by CTC criteria but PSMA-617 targeted TAT studies indicate that xerostomia, and possibly dry eyes, are the most clinically relevant toxicities to date. Mitigation strategies for these toxicities are ongoing but nothing promising has been published. Longer term data are needed to make definitive conclusions regarding toxicity but given that long term survival of advanced CRPC is problematic, there is limited concern about long term toxicities in patients with poor prognosis.
As TAT develops as a monotherapy, one can readily visualize potential synergistic opportunities developing in a manner similar to 223 Ra. Combinations with external beam, hormonal therapies, radiation sensitizers, various DNA repair inhibitors, chemotherapies, and immunotherapies will likely develop in the future.
